Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials

Title:Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials

Volume: 15 Issue: 2

Author(s): Morag E. Brookes*, Sam Eldabe and Alan Batterham

Affiliation:

• Department of Anaesthesia and Pain Management, The James Cook University Hospital, Middlesbrough, TS4 3BW,,United Kingdom

Keywords: Ca²⁺ channel blocker, MVIIA, neuropathic pain, omega conotoxin, Prialt, SNX-111, ziconotide.

Abstract: Introduction: Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain.

Methods: EMBASE, MEDLINE, CINAHL Plus and Web of Science electronic databases were searched for English language studies. Reference sections of articles were examined for further papers and the manufacturer of ziconotide was contacted for further unpublished data. Three randomised controlled trials in ziconotide monotherapy were included and subjected to a random effects meta-analysis.

Results: All three studies used the similar main outcome measure (visual analogue scale of pain intensity; VASPI) and were therefore comparable. A Jadad score was performed for each paper. Frequent serious adverse events (SAEs) were observed which resulted in two of the studies revising the protocol. The metaanalysis revealed a pooled odds ratio (responders on ziconotide vs. placebo) of 2.77 (95% CI, 1.37 to 5.59).

Discussion: The results suggest that ziconotide is beneficial for pain reduction in chronic neuropathic pain. However, there remain some methodological issues that may call into question the validity of the results. It is evident that more work needs to be conducted to further validate the efficacy of ziconotide and to discover new areas of use.

Cite this article as:

Brookes E. Morag*, Eldabe Sam and Batterham Alan, Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials, Current Neuropharmacology 2017; 15 (2) . https://dx.doi.org/10.2174/1570159X14666160210142056

DOI https://dx.doi.org/10.2174/1570159X14666160210142056	Print ISSN 1570-159X
Publisher Name Bentham Science Publisher	Online ISSN 1875-6190